Examination of stability and compatibility of flucloxacillin (Floxapen®) and ceftazidime (Fortum®) in two infusion media: Relevance for the clinical praxis;Prüfung von stabilität und kompatibilität von flucloxacillin (Floxapen®) und ceftazidim (Fortum®) in zwei infusionslösungen: Relevanz für die klinische praxis

Wiener Medizinische Wochenschrift

Volumn 155, Issue 13-14, 2005, Pages 337-343

  Thalhammer, Florian ^a   Maier Salamon, Alexandra ^b   Jäger, Walter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ceftazidime; Continuous infusion; Flucloxacillin; Furosemide; Stability

Indexed keywords

CEFTAZIDIME; FLUCLOXACILLIN; FUROSEMIDE; SODIUM CHLORIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL PRACTICE; DRUG DEGRADATION; DRUG INCOMPATIBILITY; DRUG STABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INFUSION; PHYSICAL CHEMISTRY; ROOM TEMPERATURE; THERMOSTABILITY;

CEFTAZIDIME; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG STABILITY; DRUG THERAPY, COMBINATION; FLOXACILLIN; FUROSEMIDE; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 23244434465     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-005-0190-4     Document Type: Article

References (29)

1. Conway SP, Brownlee KG, Denton M, Peckham DG (2003) Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2(4): 321-332
2. Rains CP, Bryson HM, Peters DH (1995) Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 49: 577-617
3. Richards DM, Brogden RN (1985) Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 105-161
4. Adu A, Armour CL (1995) Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Drugs 50: 423-439
5. Sutherland R, Croydon EA, Rolinson GN (1970) Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. Br Med J 214(733): 455-460
6. McNeil JJ, Grabsch EA, McDonald MM (1999) Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. Med J Aust 170(6): 270-273
7. Howden BP, Richards MJ (2001) The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 48(2): 311-314
8. Leder K, Turnidge JD, Korman TM, Grayson ML (1999) The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 43(1): 113-118
9. MacGowan AP, Bowker KE (1998) Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 35(5): 391-402
10. Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43: 523-527
11. Das Gupta V, Bethea C, de la Torre M (1988) Chemical stabilities of cefoperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 13(3): 199-205
12. Stiles ML, Tu YH, Allen LV Jr (1989) Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm 46(7): 1408-1412
13. Wade CS, Lampasona V, Mullins RE, Parks RB (1991) Stability of ceftazidime and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 48(7): 1515-1519
14. Stewart JT, Warren FW, Johnson SM, Fox JL, Mullaney J (1992) Stability of ceftazidime in plastic syringes and glass vials under various storage conditions. Am J Hosp Pharm 49(11): 2765-2768
15. Stiles ML, Alien LV Jr, Fox JL (1992) Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm 49(11): 2761-2764
16. Inagaki K, Gill MA, Okamoto MP, Takagi J (1992) Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm 49(11): 2769-2772
17. Zhou M, Notari RE (1995) Influence of pH, temperature, and buffers on the kinetics of ceftazidime degradation in aqueous solutions. J Pharm Sci 84(5): 534-538
18. Arsene M, Favetta P, Favier B, Bureau J (2002) Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions. J Clin Pharm Ther 27(3): 205-209
19. Pleasants RA, Vaughan LM, Williams DM, Fox JL (1992) Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion. Ann Pharmacother 26(10): 1221-1226
20. Servais H, Tulkens PM (2001) Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 45(9): 2643-2647
21. Elmore RL, Contois ME, Kelly J, Noe A, Poirier A (1996) Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 18(2): 246-255
22. Lynn B (2002) Recent work on parenteral penicillins. J Hosp Pharm 29: 183-194
23. Janknegt R, Stratermans T, Cilissen J, Lohman JJ, Hooymans PM (1991) Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl Sci 13(5): 207-209
24. Droste JC, Jeraj HA, MacDonald A, Farrington K (2003) Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 51(4): 849-855
25. To TP, Garrett MK (1998) Stability of flucloxacillin in a Hospital in the Home program. Australian Journal of Hospital Pharmacy 28: 289-290
26. Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM (2003) Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46 (8): 2327-2332
27. Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM (2003) Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 51 (3): 651-658
28. U.S. Pharmacopeial Convention (1995) Pharmacopeia of the United States of America (the national formulary). U.S. Pharmacopeial Convention, Rockville, MD
29. European Pharmacopoeia (2005) European Directorate for the Qualitity Medicines (EDQM) of the councils of Europe, Strasbourg, France